Skip to menu Skip to content Skip to footer
Dr Drew Neavin
Dr

Drew Neavin

Email: 

Overview

Background

Dr Drew Neavin is an NHMRC Early Leadership Fellow and the Group Leader of the Context-dependent Genetics Lab at the University of Queensland Institute for Molecular Bioscience.

Drew integrates statistical genetics with stem cell platforms and single-cell technologies to expand our understanding of genetic regulation across different contexts. She helped establish "village-in-a-dish" stem cell systems that enable high-throughput stem cell culture while reducing technical variability by co-culturing induced pluripotent stem cell lines from hundreds of individuals in a single cell culture dish. She applies this system along with other experimental models to study genetic regulation. She works across multiple disease systems with focuses in neuopsychiatric and cardiac, with a special focus on genetic modulation of drug response. She is keen to build large-scale resources that enable population genetics interrogation that consider diversity across multiple different axes.

Availability

Dr Drew Neavin is:
Available for supervision

Research interests

  • STEM PGx: stem cell pharmacogenomic platforms

    Adverse drug reactions remain a major barrier to safe and effective therapy, with substantial inter-individual variability in toxicity risk. This project will apply population-scale stem cell-derived cellular platforms to systematically map genetic determinants of drug-induced toxicity. Profiling hundreds of genetically diverse donor lines under defined drug exposures will reveal molecular signatures and genetic variants that predict susceptibility to adverse reactions. These models provide a scalable framework for functional pharmacogenomics and precision drug safety.

  • Bipolar Genetics: Population-scale brain organoids for bipolar disorder and drug response

    Although 70-90% of the chance of developing bipolar disorder is inherited, characterising the molecular mechanisms driving disease development and response to therapies has been challenging. This project uses a large cohort of iPSC-derived brain organoids to investigate how genetic background influences transcriptional programs relevant to disease biology and mood stabiliser response. By integrating single-cell transcriptomics with genomic variation across many individuals, this project aims to identify biomarkers of treatment response and uncover context-dependent regulatory mechanisms in bipolar disorder.

  • SNAPSHOT: Revealing the impact of biological variables on molecular phenotypes

    Genetic effects are shaped by biological context, including ancestry, sex, cellular state, and environmental exposure. This project uses thousands of single-cell samples to study how these variables influence molecular phenotypes such as gene expression and regulatory variation. This project aims to quantify how biological diversity modifies genetic contributes to variability in health and disease.

Works

Search Professor Drew Neavin’s works on UQ eSpace

27 works between 2018 and 2026

21 - 27 of 27 works

2021

Journal Article

Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings

Athreya, Arjun P., Brückl, Tanja, Binder, Elisabeth B., John Rush, A., Biernacka, Joanna, Frye, Mark A., Neavin, Drew, Skime, Michelle, Monrad, Ditlev, Iyer, Ravishankar K., Mayes, Taryn, Trivedi, Madhukar, Carter, Rickey E., Wang, Liewei, Weinshilboum, Richard M., Croarkin, Paul E. and Bobo, William V. (2021). Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. Neuropsychopharmacology, 46 (7), 1272-1282. doi: 10.1038/s41386-020-00943-x

Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings

2020

Journal Article

Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes

Ahmed, Ahmed T., MahmoudianDehkordi, Siamak, Bhattacharyya, Sudeepa, Arnold, Matthias, Liu, Duan, Neavin, Drew, Moseley, M. Arthur, Thompson, J. Will, Williams, Lisa St John, Louie, Gregory, Skime, Michelle K., Wang, Liewei, Riva-Posse, Patricio, McDonald, William M., Bobo, William V., Craighead, W. Edward, Krishnan, Ranga, Weinshilboum, Richard M., Dunlop, Boadie W., Millington, David S., Rush, A. John, Frye, Mark A. and Kaddurah-Daouk, Rima (2020). Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes. Journal of Affective Disorders, 264, 90-97. doi: 10.1016/j.jad.2019.11.122

Acylcarnitine metabolomic profiles inform clinically-defined major depressive phenotypes

2020

Journal Article

Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder

Qin, Sisi, Eugene, Andy R., Liu, Duan, Zhang, Lingxin, Neavin, Drew, Biernacka, Joanna M., Yu, Jia, Weinshilboum, Richard M. and Wang, Liewei (2020). Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. Clinical Pharmacology and Therapeutics, 107 (3), 662-670. doi: 10.1002/cpt.1692

Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder

2019

Journal Article

Pharmacogenomics-driven prediction of antidepressant treatment outcomes: a machine-learning approach with multi-trial replication

Athreya, Arjun P., Neavin, Drew, Carrillo-Roa, Tania, Skime, Michelle, Biernacka, Joanna, Frye, Mark A., Rush, A. John, Wang, Liewei, Binder, Elisabeth B., Iyer, Ravishankar K., Weinshilboum, Richard M. and Bobo, William V. (2019). Pharmacogenomics-driven prediction of antidepressant treatment outcomes: a machine-learning approach with multi-trial replication. Clinical Pharmacology and Therapeutics, 106 (4), 855-865. doi: 10.1002/cpt.1482

Pharmacogenomics-driven prediction of antidepressant treatment outcomes: a machine-learning approach with multi-trial replication

2019

Journal Article

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients

Bhattacharyya, Sudeepa, Ahmed, Ahmed T., Arnold, Matthias, Liu, Duan, Luo, Chunqiao, Zhu, Hongjie, Mahmoudiandehkordi, Siamak, Neavin, Drew, Louie, Gregory, Dunlop, Boadie W., Frye, Mark A., Wang, Liewei, Weinshilboum, Richard M., Krishnan, Ranga R., Rush, A. John and Kaddurah-Daouk, Rima (2019). Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients. Translational Psychiatry, 9 (1) 173, 1-14. doi: 10.1038/s41398-019-0507-5

Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients

2019

Journal Article

Pharmacogenomic next-generation DNA sequencing: Lessons from the identification and functional characterization of variants of unknown significance in CYP2C9 and CYP2C19

Devarajan, Sandhya, Moon, Irene, Ho, Ming-Fen, Larson, Nicholas B., Neavin, Drew R., Moyer, Ann M., Black, John L., Bielinski, Suzette J., Scherer, Steven E., Wang, Liewei, Weinshilboum, Richard M. and Reid, Joel M. (2019). Pharmacogenomic next-generation DNA sequencing: Lessons from the identification and functional characterization of variants of unknown significance in CYP2C9 and CYP2C19. Drug Metabolism and Disposition, 47 (4), 425-435. doi: 10.1124/dmd.118.084269

Pharmacogenomic next-generation DNA sequencing: Lessons from the identification and functional characterization of variants of unknown significance in CYP2C9 and CYP2C19

2018

Journal Article

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: Metabolomics-informed genomics

Liu, Duan, Ray, Balmiki, Neavin, Drew R., Zhang, Jiabin, Athreya, Arjun P., Biernacka, Joanna M., Bobo, William V., Hall-Flavin, Daniel K., Skime, Michelle K., Zhu, Hongjie, Jenkins, Gregory D., Batzler, Anthony, Kalari, Krishna R., Boakye-Agyeman, Felix, Matson, Wayne R., Bhasin, Swati S., Mushiroda, Taisei, Nakamura, Yusuke, Kubo, Michiaki, Iyer, Ravishankar K., Wang, Liewei, Frye, Mark A., Kaddurah-Daouk, Rima and Weinshilboum, Richard M. (2018). Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: Metabolomics-informed genomics. Translational Psychiatry, 8 (1) 56, 8. doi: 10.1038/s41398-017-0056-8

Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: Metabolomics-informed genomics

Funding

Current funding

  • 2026 - 2028
    Building the world's largest bipolar Stem Cell resource to elucidate disease risk and therapy response
    NHMRC IDEAS Grants
    Open grant
  • 2026 - 2030
    Stem cell model systems to reflect global diversity and unlock equitable cardiovascular disease research
    NHMRC Investigator Grants
    Open grant

Supervision

Availability

Dr Drew Neavin is:
Available for supervision

Looking for a supervisor? Read our advice on how to choose a supervisor.

Available projects

  • Bipolar Genetics: Population-scale brain organoids for bipolar disorder and drug response

    Although 70-90% of the chance of developing bipolar disorder is inherited, characterising the molecular mechanisms driving disease development and response to therapies has been challenging. This project will leverage induced pluripotent stem cell-derived mini brain organoids exposed to different bipolar therapies to identify genetic variations that alter therapeutic response.

    This PhD project includes working with the Neavin stem cell wet lab team to design and carry out large-scale stem cell experiments before capturing with single-cell technologies and analysis of the single-cell data. As a result, the successful candidate will gain critical cross-training in wet lab techniques and computational analyses making them highly sought after for future positions. Being located in teh Centre for Population and Disease Genomics will provide a rigorous statistical environment to support additional learning and skills development

  • Stem cell villages for population-scale stem cell modelling

    Population genomics work have identified thousands of genomic regions associated with human traits. However, it's been challenging to link these genetic regions to genes since >90% of these associated regions are outside of genes suggesting they impact gene expression but making it challenging to identify the specific gene impacting the trai. In addition, genetic regions do not regulate gene expression the same way in all cell types meaning that the relevant cell type is important to understanding the impact of these genetic regions on different human traits.

    The Neavin Group uses stem cell models differentiated into specific cell types across hundreds of donors to identify variants that impact gene expression to link genetic regions to specific genes regulating gene expression to link them to human traits. However, stem cell culture is expensive and time-consuming so we and others have developed 'village-in-a-dish' approaches that co-culture stem cell lines from different individuals in one dish to scale stem cell models without increasing cost. While effective, there are still limitations with these models that can be optimised.

    This project will build on the village system to develop approaches to make these co-culture approaches more robust and reveal line-specific characteristics that result in cell culture dominance. The successful PhD candidate will learn stem cell culture techniques and work with the Neavin wet lab team to carry out stem cell village experiments. This project also includes analysis of the resulting data providing the PhD student with a diverse skillset across wet lab and dry lab approaches.

  • Revealing the impact of biological variables on molecular phenotypes

    Genetic effects are shaped by biological context, including ancestry, sex, cellular state, and environmental exposure. To assess this at scale, we leverage single-cell data from >100 million cells and >10k individuals to understand how genetic effects are altered.

    This PhD project builds on previous work Drew did understanding the diversity of single-cell atlases and the impact on biological signals. This PhD student will process publicly available data using an established pipeline and combine and anlyse the results giving the student a strong foundation in large-scale analyses, single-cell analysis and statistical genetics.

  • Diverse pharmacogenomic functional validation

    Multiple genes are known to have a large impact on response to therapies, known as pharmacogenomics, with >99% of individuals estimated to have a drug altering genetic allele. Most pharmacogenomic studies have been carried out in European ancestries but these genes are known to be highly polymorphic across populations so characterisation of genetic alleles in non-European populations is critical.

    This PhD project is part of a large collaborative project across Australia to characterise novel pharmacogenomic allele function using stem cell-derived ccells. This PhD student will work with other researchers in the network to identify likely-impactful variants and test them with stem cell models. This PhD student will gain a strong basis in stem cell modelling and have the opportunity to work as part of a large collaborative network.

  • Stem cell villages for ALS drug development

    Amyotrophic lateral sclerosis (ALS) is a fatal, heterogeneous neurodegenerative disease caused by progressive death of motor neurons. However, the genetic underpinnings are unknown for many patients making therapeutic selection or development challenging. Stem cell-derived motor neurons are a strong model system for understanding molecular mechanisms and identifying therpeutic targets for ALS.

    This PhD project will use an exciting combination of stem cell village, single-cell technology, long-read sequencing, CRISPR approaches and molecular imaging to model ALS and identify potential therapeutic targets for ALS. This proejct will provide a strong host of stem cell and molecular biology skills for the successful candidate. This is part of an international collaboration which will give the student a wide network and experience working with different field experts.

Supervision history

Current supervision

Media

Enquiries

For media enquiries about Dr Drew Neavin's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au